vascularization

Mecamylamine hydrochloride (Mevasin) 是一种易穿过血脑屏障的烟碱拮抗剂，用作高血压的神经节阻滞剂，具有抗神经疾病作用。

Deferoxamine Mesylate (DFOM) 是一种铁螯合剂和铁死亡抑制剂。Deferoxamine Mesylate 可将游离铁结合成稳定的复合物，减少铁的积累。Deferoxamine Mesylate 可以上调 HIF-1α 水平，诱导细胞凋亡。

INCA-6 (Triptycene-1,4-quinone) 是细胞渗透性的 NFAT 抑制剂。INCA-6 通过特异性阻断 NFAT 底物靶向钙调神经磷酸酶位点，有效抑制calcineurin (CN)-NFAT 信号传导。

Bucillamine (DE019) 可防止高危器官移植中的缺血/再灌注损伤，抑制 VEGF 的产生。 Bucillamine 是一种具有抗风湿和抗血管生成特性的口服活性巯基供体和抗氧化剂。 Bucillamine 可用于脉络膜新生血管和类风湿性关节炎的研究。

Ned 19, a selective membrane-permeant non-competitive antagonist of NAADP, strongly inhibits tumor growth, vascularization, and lung metastases in mice.

Avitinib (AC0010) 是一种不可逆的、突变体选择性的EGFR 抑制剂，可有效抑制非小细胞肺癌中EGFR T790M 耐药突变。阿比替尼也是一种新型BTK 抑制剂。

Bevasiranib 是一种siRNA，可沉默产生血管内皮生长因子(VEGF)的基因。VEGF 在脉络膜新生血管形成(choroidal neo-vascularization, CNV)的发病机制中起着关键作用，而CNV 是湿性年龄相关性黄斑变性(wet age-related macular degeneration, wet AMD)的前兆。

Bevasiranib sodium 是一种siRNA，可沉默产生血管内皮生长因子(VEGF)的基因。VEGF 在脉络膜新生血管形成(choroidal neo-vascularization, CNV)的发病机制中起着关键作用，而CNV 是湿性年龄相关性黄斑变性(wet age-related macular degeneration, wet AMD)的前兆。

QLT0267 is an inhibitor targeting integrin-linked kinase (ILK; IC50= 26 nM), showing over 10-fold selectivity against cyclin-dependent kinases 1, 2, and 5 (Cdk1, Cdk2, and Cdk5), and over 1,000-fold selectivity against C-terminal Src kinase (CSK), DNA-PK, Pim-1, Akt, PKC, and casein kinase 2 (CK2) at a concentration of 10 mg/ml. This compound effectively inhibits the proliferation of NPA187 papillary thyroid cancer cells with an IC50 of approximately 3 µM and induces apoptosis in NPA187, DRO, and K4 cancer cell lines. In vivo studies reveal that QLT0267, administered at 100 mg/kg, significantly reduces tumor growth in a DRO mouse xenograft model and diminishes both tumor volume and intratumoral vascularization in a U87MG glioblastoma mouse xenograft model, showcasing its potential for therapeutic applications in cancer treatment.